Anxiety Medications: SSRIs and SNRIs Explained, A Doctor-Reviewed Guide

SSRIs and SNRIs are the most commonly prescribed medications for anxiety disorders worldwide and are first-line pharmacological treatments according to NICE, the American Psychiatric Association, and other major guideline bodies. They are also among the most misunderstood medications in everyday conversation. This guide covers what these medications are, how they work, the named drugs in each class with their Indian brand names, the side effects to expect (initial and ongoing), the safety considerations including the serious risks (serotonin syndrome, suicidality warning in young people), the discontinuation syndrome and how to taper, and how long to stay on them. This is educational content. Medication decisions require individual assessment by a qualified prescriber.

What SSRIs and SNRIs are

SSRIs (selective serotonin reuptake inhibitors) and SNRIs (serotonin-norepinephrine reuptake inhibitors) are two related classes of medication. They were originally developed for depression in the late 1980s and 1990s, hence the historical label "antidepressants." Subsequent research established them as equally effective for anxiety disorders, OCD, and several other conditions. The "antidepressant" label persists but is misleading; these medications are first-line treatments for anxiety regardless of whether depression is present.

The two classes share a similar overall safety profile and similar effectiveness for most anxiety conditions. SNRIs add some effect on norepinephrine (also called noradrenaline) which can be helpful for certain presentations, particularly when fatigue or chronic pain coexists. SSRIs are often started first because of their well-established safety record and longer track record.

How they work

Both classes work by blocking the reuptake of neurotransmitters. After a brain cell releases serotonin (or noradrenaline in the case of SNRIs) into the synaptic space between cells, the releasing cell normally reabsorbs much of it within seconds. SSRIs and SNRIs block this reabsorption, leaving more of the neurotransmitter available in the synaptic space.

The neurotransmitter changes happen within hours of the first dose, but clinical improvement in anxiety takes 2 to 8 weeks. This delay is one of the most consequential features of the medications. The current understanding is that the immediate neurotransmitter changes trigger downstream adaptations in receptor sensitivity, gene expression, neuroplasticity, and brain circuit function that take weeks to manifest as symptom improvement. The exact mechanism by which these downstream changes reduce anxiety is incompletely understood, though it is well-evidenced that they do.

The SSRIs (with India brand names)

Sertraline and escitalopram are the most commonly prescribed SSRIs in India for anxiety. Brand names vary by manufacturer; generic equivalents are widely available and substantially cheaper than branded preparations. Generic substitution is usually appropriate but should be discussed with the prescriber.

The SNRIs (with India brand names)

Venlafaxine and duloxetine are the most commonly prescribed SNRIs in India for anxiety. Venlafaxine has a shorter half-life and produces more discontinuation symptoms than most SSRIs; gradual tapering is particularly important when stopping.

Anxiety conditions treated

SSRIs and SNRIs have evidence for and are commonly prescribed in:

• Generalised anxiety disorder (GAD)
• Panic disorder
• Social anxiety disorder
• Obsessive-compulsive disorder (OCD)
• Post-traumatic stress disorder (PTSD)
• Mixed anxiety and depression
• Agoraphobia (usually as part of panic disorder treatment)
• Body dysmorphic disorder and other related conditions
• Perinatal anxiety and depression (with specific medication considerations)

Specific phobias usually respond best to exposure therapy without medication, though SSRIs may help when phobias coexist with broader anxiety or depression. See our phobias guide for more.

Onset of action and dose titration

Standard prescribing practice involves starting at a low dose, increasing gradually over weeks. The reasons are: to allow assessment of side effect tolerance, to reduce the temporary anxiety worsening that can occur in the first 1 to 2 weeks, and to find the lowest dose that produces benefit.

Typical patterns:

• Sertraline: start 25 mg for 7 days, increase to 50 mg; review at 4 to 6 weeks, increase further if needed
• Escitalopram: start 5 mg for 7 days, increase to 10 mg; review at 4 to 6 weeks
• Venlafaxine XR: start 37.5 mg, increase to 75 mg after 1 week; further increase based on response and blood pressure

These are general patterns, not prescribing recommendations. Individual prescribing depends on the specific condition, the patient's other health factors, prior medication response, and clinical judgement of the prescribing doctor.

Initial side effects (first 1-2 weeks)

Early side effects are common and usually improve over the first 2 to 4 weeks as the body adjusts. The most common include:

Ongoing side effects

After the initial adjustment period, the side effects that may persist include:

• Sexual dysfunction: reduced libido, delayed or absent orgasm, erectile difficulties. Affects a substantial minority of patients and often persists. Strategies include lower doses, switching to medications with less sexual impact (vortioxetine, bupropion, mirtazapine are non-SSRI/SNRI options sometimes considered), or accepting and managing the effect. Discuss openly with prescriber; this is a common reason for non-adherence that often goes undiscussed.
• Weight changes: some weight gain over months is common with most SSRIs, more pronounced with paroxetine. Weight loss can occur initially with some agents. Lifestyle and exercise factors influence the net effect.
• Mild sweating: may persist for some patients.
• Emotional blunting: reduced intensity of emotional responses, both positive and negative. Often described as "flatness." More common at higher doses; may improve with dose reduction.
• Fatigue: can persist in a minority of patients.
• Bleeding risk: SSRIs and SNRIs mildly increase the risk of bleeding, particularly with NSAIDs (ibuprofen, diclofenac), anticoagulants, or anti-platelet medications. Usually small absolute risk but worth knowing.
• Bone density: long-term use is associated with slightly lower bone density. Relevant for elderly patients and those at fracture risk.
• SNRI-specific: blood pressure increase, particularly with venlafaxine at higher doses. Monitoring at higher doses is standard.

Most patients tolerate ongoing treatment well. When side effects are limiting, options include dose reduction, switching to a different agent in the same class, or considering alternatives.

Serotonin syndrome and MAOI interaction

Serotonin syndrome is a potentially serious condition caused by excessive serotonin activity. It is rare with SSRI or SNRI use alone at therapeutic doses but can occur when these medications are combined with other serotonergic drugs.

Most dangerous combination: monoamine oxidase inhibitors (MAOIs), an older class of antidepressants. Combining SSRIs or SNRIs with MAOIs can produce severe serotonin syndrome including high fever, muscle stiffness, tremor, confusion, seizures, autonomic instability, and rarely death. A washout period of at least 2 weeks (5 weeks for fluoxetine due to its long half-life) is required between stopping one and starting the other.

Other serotonergic medications that can contribute to serotonin syndrome when combined:

• Tramadol (painkiller used for moderate pain, commonly prescribed in India)
• Triptans (migraine medications: sumatriptan, rizatriptan)
• St John's Wort (herbal supplement sometimes used for mood)
• Lithium
• Linezolid (antibiotic used for resistant infections)
• Some opioids (fentanyl, pethidine)
• MDMA and similar recreational drugs

Symptoms suggesting serotonin syndrome requiring urgent assessment: fever, muscle stiffness or twitching, tremor, agitation, confusion, fast heart rate, sweating, dilated pupils, gastrointestinal symptoms. If you develop these after starting a new medication or combining medications, contact your prescriber or go to an emergency department.

Always inform prescribers about all medications (prescription, over-the-counter, herbal) before starting an SSRI or SNRI. The combination of casual tramadol use plus a new SSRI is a real-world risk in India where tramadol is sometimes used informally for pain.

Suicidality warning in young people

In 2004, the US FDA added a "black box" warning to SSRIs and SNRIs regarding a small but real risk of new or worsening suicidal thoughts in children, adolescents, and young adults (under 25) during the first weeks of treatment. The warning was based on pooled clinical trial data.

The current understanding:

• The absolute risk is small (an increase of around 1 to 2 percent in suicidal thinking, mostly without action, in children and adolescents in clinical trials)
• The risk is more relevant in depression than in anxiety
• The benefits of treating depression and anxiety in young people, including reducing suicide risk overall, usually substantially outweigh the small medication-associated risk
• Initial monitoring (weekly or every 2 weeks for the first 4 to 6 weeks) is standard for young people starting these medications
• Family members should be informed about what to watch for: new or worsening suicidal thoughts, severe agitation, marked behaviour change

The warning has had complicated effects. After it was introduced, prescribing decreased; some analyses suggest youth suicide rates increased during that period as untreated depression became more common. The current professional consensus is that medication should be available when indicated, with appropriate monitoring, and the warning should not deter appropriate treatment.

For more detail on anxiety in young people, see our anxiety in children and teens guide.

Other drug interactions

Beyond MAOIs and serotonergic medications, other interactions to be aware of:

• NSAIDs and anticoagulants: SSRIs and SNRIs combined with ibuprofen, diclofenac, aspirin, or warfarin increase bleeding risk. Use proton-pump inhibitors when long-term NSAID use is required; monitor INR with warfarin.
• QT-prolonging medications: citalopram and escitalopram can prolong the cardiac QT interval, particularly at higher doses. Combination with other QT-prolonging drugs (some antibiotics, antiemetics, antipsychotics) increases risk of arrhythmia.
• Phenytoin, carbamazepine, and some other anticonvulsants: can affect SSRI levels.
• Some HIV medications (ritonavir): can substantially increase SSRI levels.
• Tamoxifen: some SSRIs (especially fluoxetine and paroxetine) reduce tamoxifen effectiveness. Important consideration in breast cancer patients.
• Alcohol: not a direct dangerous interaction in most cases, but alcohol may worsen anxiety, depression, and sleep, partly offsetting medication benefit. Generally not recommended to drink heavily on these medications.

Always provide a complete medication list including over-the-counter products and supplements to your prescriber and pharmacist.

Pregnancy and breastfeeding

SSRIs in pregnancy and breastfeeding involve careful risk-benefit assessment. Untreated severe anxiety and depression have documented effects on pregnancy outcomes and child development. Many SSRIs have substantial safety data in pregnancy, with sertraline often a first-line choice.

Key principles:

• Sertraline is often considered a first-line choice in pregnancy and breastfeeding due to safety profile
• Paroxetine carries more concerning fetal cardiac data and is usually avoided in first trimester where alternatives exist
• Benzodiazepines are generally avoided in pregnancy
• Do not stop SSRIs abruptly on learning of pregnancy without medical advice; this often causes more harm than continuing
• The LactMed database (US National Library of Medicine) provides current evidence on breastfeeding compatibility for specific medications
• Decisions should be made with a psychiatrist working with the obstetrician, and the paediatrician where breastfeeding-related questions arise

This area is covered in detail in our anxiety during pregnancy and postpartum guide.

Children and adolescents

SSRIs have evidence in paediatric anxiety disorders, with sertraline, fluoxetine, and escitalopram having the most data. Medication decisions for minors involve specific considerations:

• CBT is first-line for paediatric anxiety; medication is added when severity warrants
• The FDA black box warning about suicidality applies to under-25; weekly monitoring for the first 4 weeks is standard
• Family discussion of benefits, side effects, and the small but real risk is essential
• Lower starting doses are used, with slower titration
• Combination of CBT plus SSRI often outperforms either alone for severe paediatric anxiety

See our anxiety in children and teens guide for fuller paediatric coverage.

Discontinuation syndrome and tapering

SSRIs and SNRIs do not cause addiction (no craving for the medication, no escalating dose required for the same effect). However, they do cause a discontinuation syndrome when stopped suddenly or tapered too quickly. This is a physical adjustment, not addiction.

Common discontinuation symptoms:

• Dizziness and unsteadiness
• "Brain zaps" (brief electric-shock sensations, particularly with eye movement)
• Flu-like feelings (aches, chills, fatigue)
• Irritability and mood changes
• Anxiety rebound
• Vivid dreams or sleep disturbance
• Gastrointestinal symptoms
• Headache
• Sensory disturbances (numbness, tingling)

Risk factors for more severe discontinuation: shorter-acting medications (paroxetine, venlafaxine), longer duration of treatment, higher doses, rapid tapering, and individual susceptibility.

Tapering strategies:

• Standard taper: reduce dose by 25 to 50 percent every 2 to 4 weeks until lowest dose, then stop
• Hyperbolic taper: for patients on long-term treatment, reducing by smaller proportions as the dose gets lower (e.g., 25 percent reductions of the current dose rather than fixed mg reductions) substantially reduces discontinuation symptoms
• Liquid formulations or compounded smaller doses: available for very gradual tapers when needed
• Fluoxetine bridge: some prescribers switch shorter-acting SSRIs to fluoxetine before stopping, taking advantage of fluoxetine's long half-life to provide a built-in taper

The most important principle: do not stop abruptly. Always work with your prescriber on a tapering plan. If you experience severe discontinuation symptoms, slowing the taper is appropriate; this is not failure, it is normal physiological adjustment.

How long to stay on them

Current guidelines for first-episode anxiety disorders responding well to SSRI or SNRI treatment recommend:

• Continue at therapeutic dose for at least 6 to 12 months after symptoms have substantially improved or remitted
• Then taper gradually with prescriber guidance
• For recurrent or chronic anxiety disorders, longer treatment (sometimes years or indefinite) may be appropriate
• The decision to stop involves discussion of current life stressors, history of relapse, side effect tolerance, and patient preference

Stopping too early increases relapse risk substantially. Many patients who stop within 6 months of feeling better experience relapse within weeks to months and require resumption of treatment, often with worse symptoms than before. The "feeling better" stage is not the same as the "treated" stage; medication needs to continue beyond symptom resolution to consolidate the underlying changes.

For some patients, ongoing or repeated courses of treatment over years is appropriate medical management of a chronic relapsing condition rather than failure. This is parallel to how blood pressure medication is often lifelong; the medication manages the condition rather than curing it.

India context

Several India-specific considerations are worth knowing.

Generic availability and cost. Generic SSRIs and SNRIs are widely available in India at substantially lower cost than branded preparations. A month of generic sertraline 50 mg may cost 50-150 rupees; the equivalent branded version may cost 200-500 rupees. Generic substitution is usually appropriate; discuss with prescriber if you are switching brands during ongoing treatment.

Stigma around taking psychiatric medication. Many Indian patients hide their prescriptions from family or workplace because of stigma. This contributes to non-adherence, early discontinuation, and worse outcomes. Increasing public understanding that these medications are similar to medications for any other chronic condition (blood pressure, diabetes) is important. The "I should be able to manage without medication" framing often delays effective treatment.

Over-the-counter availability concerns. SSRIs and SNRIs are Schedule H prescription-only medications in India, but in practice some pharmacies dispense them without verifying prescriptions. This is unsafe; these medications need proper assessment and monitoring. Avoid pharmacy-only purchases.

Tramadol risk. Tramadol is commonly prescribed or self-administered for pain in India. The combination of tramadol with SSRIs or SNRIs increases serotonin syndrome risk. Always tell prescribers about pain medication use.

St John's Wort and Ayurvedic preparations. Some traditional or herbal preparations interact with SSRIs. Brahmi (Bacopa monnieri) and Ashwagandha have limited interaction data with SSRIs but warrant disclosure. St John's Wort can cause serotonin syndrome with SSRIs and should be avoided.

Access to psychiatric care. India has approximately 1 to 2 psychiatrists per 100,000 population, well below global average. For many patients, the prescribing pathway is via general physician or family doctor. This is appropriate for straightforward cases; complex cases, paediatric prescribing, pregnancy considerations, and treatment-resistant cases warrant psychiatric referral. Telemedicine has expanded access substantially.

Common myths

Red flags warranting urgent contact

• New or worsening suicidal thoughts, particularly in the first 4 weeks of treatment or after dose change. Contact prescriber, helpline, or emergency department immediately.
• Symptoms suggesting serotonin syndrome (fever, muscle stiffness, tremor, confusion, fast heart rate, sweating, dilated pupils), particularly after starting a new medication or combination.
• Severe rash, swelling, breathing difficulty (allergic reaction).
• Persistent severe nausea, vomiting, or inability to eat after starting the medication.
• Severe sleep disruption substantially affecting functioning.
• New severe agitation or restlessness (akathisia).
• Sustained marked blood pressure increase, particularly on SNRIs.
• Severe discontinuation symptoms after stopping or missing doses.
• Marked behavioural change in young people on these medications.
• Any unusual bleeding or bruising (particularly with concurrent NSAID, aspirin, or anticoagulant use).

A note from Dr. Boppana Sridhar

Three patterns come up repeatedly in OPD with these medications. The first is patients stopping early, usually within 2 to 4 weeks, because they have not felt the benefit yet and have read about side effects. Spending time before the prescription explaining the 2 to 8 week onset, the initial side effect adjustment, and the importance of continuing past the early phase substantially improves outcomes. The second is patients stopping abruptly when they feel better, often around 3 to 6 months, without tapering. This produces both discontinuation symptoms and a high relapse rate within weeks to months. The 6 to 12 month minimum after feeling better is genuine science, not arbitrary caution. The third is patients hiding their prescriptions from family members because of stigma, leading to inconsistent dosing, missed doses, and worse outcomes. Helping the patient have the conversation with one supportive family member, where culturally possible, transforms adherence and recovery. Medication is one tool among several for treating anxiety. CBT works without it for many patients; lifestyle factors matter; trigger management matters. But when medication is indicated, taking it properly produces real benefit. The middle ground between rejecting medication entirely and over-medicating is what I aim for in OPD.

Frequently asked questions

Related reading on 247healthcare.blog

• Mental Health and Primary Care: the hub
• Anxiety Disorders: the pillar
• What is Generalised Anxiety Disorder (GAD)?
• Anxiety Symptoms: Physical Signs Explained
• Panic Attack vs Heart Attack
• Social Anxiety Disorder Symptoms
• Phobias: Common Types and Treatment
• Anxiety in Children and Teens
• Anxiety During Pregnancy and Postpartum
• Anxiety Triggers: How to Identify Them

References

1. National Institute for Health and Care Excellence (NICE). Generalised anxiety disorder and panic disorder in adults: management. NICE CG113.
2. NICE CG159. Social anxiety disorder: recognition, assessment and treatment.
3. US Food and Drug Administration (FDA). Drug Safety and Availability, including SSRI black box warning.
4. British National Formulary (BNF). SSRI and SNRI prescribing reference.
5. American Psychiatric Association. Anxiety Disorders patient and family resources.
6. LactMed Database (US National Library of Medicine). Drug and lactation database.
7. NHS UK. Medicines A to Z reference.
8. WHO Mental Health Gap Action Programme (mhGAP) prescribing guidance.